Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from
FinraMoving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
Summary:
- MACD is crossing MACD signal line at 0.6. MACD crossing signal line is bullish signal.
| MarketCap | 17.8B |
|---|---|
| PE Ratio | 8.7 |
| PEG Ratio | -1.4 |
| P/B | 2.5 |
| P/S (ttm) | 1.5 |
| Earning Growth (QoQ) | 374% |
| Revenue Growth (QoQ) | |
| Short % | 9% |
| Held by Institutions % | 93% |
| 1 Day Vol Adjusted Return | -0.9 |
| 1 Month Vol Adjusted Return | -4.1 |
| 3 Month Vol Adjusted Return | 4.3 |
| 6 Month Vol Adjusted Return | 10.8 |
| 20 Days SMA Price ZScore | 0.4 |
| 50 Days SMA Price ZScore | -0.8 |
| 12 -26 Days PPO | -1.0 |
| 1 Month Average Short Volume Ratio | 47.0 |
| 1 Day Volume Change ZScore | 1.9 |
| 1 Month Daily Vol | 1.2 |
Stock news
When it comes to the well-being of our employees, mental and emotional health are just as important as physical wellness. With the increased prevalence of mental health issues in connection with CO...
The entire contents of the call, including the presentation and question-and-answer session that will follow, are the copyrighted property of Quest Diagnostics with all rights reserved. Any redistribution, retransmission or rebroadcast of this call in any form without the written consent of Quest Diagnostics is strictly prohibited. Now, I would like to introduce Shawn Bevec, Vice President of Investor Relations for Quest Diagnostics.
Quest Diagnostics (DGX) notes that in late summer it experienced some softness in the base business across the country but recovered in September.
View more earnings on DGXSee more from BenzingaClick here for options trades from BenzingaDanaher's Q3 Earnings Beats Street EstimatesTenet Achieves Quarterly Operating Income Of B, Raises FY21 Outlook© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Quest Diagnostics (DGX) delivered earnings and revenue surprises of 33.78% and 12.56%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Quest Diagnostics Inc on Thursday warned that demand for COVID-19 molecular testing will slow down through the end of 2021 as infections decline, but a recovery in its core testing business will likely cushion the blow. Shares of the U.S. laboratory reversed course and fell 3.5% to $141.75 in early trading after it said it expects to record about 50,000 molecular tests per day in the fourth quarter.
Quest Diagnostics Inc. said Thursday its third-quarter net income fell to $505 million, or $4.02 a share, from $568 million, or $4.14 a share in the year-ago quarter. Adjusted earnings fell to $3.96 a share from $4.31 a share. Revenue at the medical testing company dropped to $2.774 billion from $2.786 billion. Analysts expected the company to earn $2.88 a share on revenue of $2.452 billion, according to a FactSet survey. Quest Diagnostics said it's lifting its 2021 profit target to a range of $
(Reuters) -Quest Diagnostics Inc on Thursday warned that demand for COVID-19 molecular testing will slow down through the end of 2021 as infections decline, but a recovery in its core testing business will likely cushion the blow. Shares of the U.S. laboratory reversed course and fell 3.5% to $141.75 in early trading after it said it expects to record about 50,000 molecular tests per day in the fourth quarter.